Document:

<PAGE>   1
                                                                    EXHIBIT 4.10

                             LCC INTERNATIONAL, INC.

                                 AMENDMENT NO. 3
                                       TO
                             LCC INTERNATIONAL, INC.
                         1996 EMPLOYEE STOCK OPTION PLAN

                             (THE "AMENDMENT NO. 3")

       LCC International, Inc. (the "Corporation") hereby amends the terms of
the LCC International, Inc. 1996 Employee Stock Option Plan (the "Plan") as
follows:

       1. Section 3.1 entitled "Committee " is amended to authorize the
delegation of authority under the Plan by the Committee to a one person
committee of the Board of Directors by the addition of a new sentence at the end
of Section 3.1 as follows:

       To the extent permitted by law, the Committee may delegate its authority
       under the Plan to a single member committee of the Board of Directors.

       2. The reference to "4,725,000" in the second sentence of Section 4 of
the Plan is replaced by "5,225,000".

                                      * * *

       This Amendment No. 3 was duly adopted and approved by the Board of
Directors of the Corporation on December 16, 1999.

                                            /s/ Peter A. Deliso
                                            ----------------------------------
                                            Vice President, General Counsel
                                            and Secretary<PAGE>   1
                                                                   Exhibit 10.28

                               RESEARCH AGREEMENT

                     CHILDREN'S HOSPITAL RESEARCH AGREEMENT

            This Agreement ("Agreement") entered into this 1st day of October,
1999 (the "Effective Date"), by and between Children's Hospital, 300 Longwood
Avenue, Boston, Massachusetts 02115-5737 ("Hospital"), and EntreMed, Inc., 9640
Medical Center Drive, Rockville, Maryland 20850 ("EntreMed").

            WHEREAS, Hospital owns certain inventions that may be useful in the
treatment of diseases in humans or animals and is interested in having a
corporate sponsor and licensee to clinically develop these inventions;

            WHEREAS, EntreMed is interested in funding and/or implementing the
clinical development of certain of the inventions in return for options for
licensing certain of the inventions;

            WHEREAS, the research program contemplated by this Agreement is of
mutual interest and benefit to Hospital and to EntreMed and may further the
practice of medicine and the research agenda of the Hospital in the manner
consistent with its status as a non-profit, tax-exempt, teaching Hospital.

            NOW, THEREFORE, the parties agree as follows:

1.          SCOPE OF WORK

            (a)         Hospital agrees to use reasonable efforts to perform the
                        Research and Clinical Development Program entitled
                        "Angiogenesis Research Program" ("Program") in
                        accordance with Exhibit A, attached hereto and made a
                        part of this Agreement, as the same may be amended by
                        the parties from time to time.

            (b)         Any alteration in or amendment to the Program must be
                        approved in writing by both Hospital and EntreMed prior
                        to such alteration or amendment being effective.

2.          PERIOD OF PERFORMANCE

            (a)         The Program shall be conducted during the period
                        beginning on the Effective Date, through September 29,
                        2002, and will be subject to renewal only by written
                        mutual agreement of EntreMed and Hospital.

3.          PRINCIPAL INVESTIGATOR
<PAGE>   2

            (a)         The Principal Investigator for the Program will
                        be Robert D'Amato, M.D., Ph.D. ("Principal
                        Investigator") of the Department of Surgery.  In
                        the event the Principal Investigator becomes
                        unable to complete the Program for any reason,
                        EntreMed and Hospital may mutually agree upon a
                        substitute Principal Investigator, in which event
                        this Agreement shall continue in full force and
                        effect.  If EntreMed and Hospital cannot agree on
                        a substitute, either party may immediately
                        thereafter terminate this Agreement, subject to
                        the requirements of Section 11(f) of this
                        Agreement.

4.          RESEARCH PROGRAM SUPPORT

            (a)         Primary Program Support. EntreMed agrees to pay Hospital
                        two million dollars (2,000,000.00) to fund the Program
                        in accordance with the conditions and terms of this
                        Agreement.

            (b)         Payments.  On October 1, 1999, EntreMed will pay
                        Hospital the sum of six hundred fifty thousand
                        four hundred ninety-one dollars ($650,491) and
                        thereafter will make payments of six hundred
                        sixty-six thousand eight hundred eighty-five dollars
                        ($666,885) on October 1, 2000 and six hundred
                        eighty-two thousand six hundred twenty four
                        dollars ($682,624) on October 1, 2001, in
                        accordance with the conditions and terms set
                        forth herein.

            (c)         Payments. Payments of all sums due hereunder shall be
                        made by check payable as follows:

                                    Children's Hospital
                                    Research Finance Office
                                    300 Longwood Avenue
                                    Boston, MA  02115-5737

            (d)         Late Payments.  Late payments shall bear interest
                        from the due date until payment at a rate of the
                        lower of one and one-half percent (1  1/2%) per
                        month, or the maximum amount permitted by law.
                        The payment of such interest shall not foreclose
                        Hospital from exercising any other rights it may
                        have as a consequence of the lateness of any
                        payment, including without limitation termination
                        under Article 11(d).

5.          EQUIPMENT

            (a)         Equipment purchased as part of the Program shall be
                        owned by the Hospital, shall be physically located at
                        the Hospital, and shall remain as property of the
                        Hospital following completion of the Program.
<PAGE>   3

6.          PUBLICATIONS

(a)         EntreMed acknowledges that Hospital is an academic
            medical center and that Dr. D'Amato and his
            collaborators shall be free to publish results of
            their studies without restraint.  Notwithstanding
            this, Hospital agrees to send EntreMed copies of any
            manuscripts resulting from the Program and submitted
            for consideration for publication or any abstracts
            that are submitted to a conference no later than the
            same day the manuscript or abstract is submitted.
            Hospital agrees to use reasonable efforts to notify
            EntreMed at least one month in advance of any
            instances where the results of the Program will be
            presented at a conference by invitation and without
            abstract.  EntreMed will notify Hospital if any action
            is necessary to secure patent protection for the
            technology and Hospital agrees to take such action,
            subject to the terms and conditions hereof.  If
            EntreMed so elects, Hospital agrees to include in any
            publication of the results of the Program
            acknowledgment of EntreMed's financial and technical
            support.

7.          INTELLECTUAL PROPERTY

            (a)         Any invention conceived or first reduced to
                        practice by Hospital or Hospital personnel in the
                        performance of the Program shall be owned by
                        Hospital ("Invention").  Any invention conceived
                        or first reduced to practice by EntreMed or
                        EntreMed personnel at EntreMed's facilities
                        during the term of this Agreement shall be owned
                        by EntreMed.  Any invention conceived or first
                        reduced to practice jointly by Hospital or
                        Hospital personnel and EntreMed or EntreMed
                        personnel shall be jointly owned by Hospital and
                        EntreMed; for jointly-owned inventions, Hospital
                        agrees to offer an option to license the
                        Hospital's interest in the invention according to
                        Section 7(c).

            (b)         Hospital agrees to notify EntreMed as soon as
                        possible when a new, potentially patentable
                        Invention has been identified and disclosed to
                        the Technology Transfer Office.  EntreMed will
                        immediately order a patentability/6 and
                        infringement search and, if the Invention is
                        patentable, will be responsible, at EntreMed's
                        expense, for filing and prosecuting patent
                        applications on behalf of Hospital in Hospital's
                        name covering the new Inventions, with
                        appropriate and timely review and approval by
                        Hospital.  EntreMed shall solicit Hospital's
                        comments prior to any significant actions
                        required during filing and prosecution and
                        provide Hospital with drafts of proposed actions
                        and responses sufficiently in advance to allow
                        time for comment and with file copies after the
                        action is completed.  If EntreMed decides not to
                        file a patent application, EntreMed will notify
                        Hospital within [ninety] [90] days of receiving
                        disclosure of the new Invention; and if EntreMed
                        decides not to maintain prosecution of any patent
                        application, EntreMed will notify Hospital in a
                        timely fashion.  Hospital may elect to file or
                        maintain prosecution of such patent rights at its
                        own expense; and Hospital shall be entitled to
                        dispose of such patent

<PAGE>   4

                        rights without limitation, and EntreMed shall have no
                        further option, license or other rights thereto.

            (c)         For inventions for which EntreMed shall elect to
                        file and maintain prosecution of a patent
                        application, Hospital grants to EntreMed an
                        exclusive nine-month option to decide whether or
                        not to negotiate an exclusive license.  Such
                        option period shall begin at the date of filing
                        of a provisional patent application or a
                        non-provisional patent application.  At the end of
                        the nine-month option period after filing of a
                        provisional patent application, EntreMed may
                        request an additional six-month option period.
                        In consideration for granting the additional
                        six-month period, EntreMed will agree to file a
                        non-provisional patent application at EntreMed's
                        expense.  If EntreMed chooses to license such
                        patent rights during either option period,
                        EntreMed shall have an additional three-month
                        period in which to negotiate and enter into a
                        license on the terms and conditions of the model
                        license agreement (Exhibit B).  During this
                        three-month period, EntreMed will provide a development
                        plan to Hospital which will include a time frame
                        for implementation of the development plan.  This
                        development plan will be updated semiannually.
                        If EntreMed chooses not to license each patent
                        rights, Hospital shall have the right to license
                        to a third party; and EntreMed shall have no
                        further option, license or other rights thereto.

            (d)         Any license granted pursuant to this Agreement shall
                        conform to the terms and conditions of the License
                        attached as Exhibit B.

            (e)         Any license granted pursuant to this Article
                        shall be subject to a reservation of the
                        unrestricted right of Hospital and inventors
                        (while employed by Hospital or other non-profit
                        institution) to use subject matter claimed in the
                        licensed patent(s) or patent application(s) for
                        research purposes only at no cost to Hospital and
                        the right to license to non-profit institutions
                        for research purposes only.

            (f)         EntreMed shall retain all invention disclosures
                        submitted by Hospital in confidence and use its best
                        efforts to prevent their disclosure to third parties.
                        EntreMed shall be relieved of this obligation only when
                        this information becomes publicly available through no
                        fault of EntreMed.

8.          INDEMNIFICATION

            (a)         EntreMed shall indemnify, defend and hold
                        harmless Hospital and its board members,
                        officers, medical staff, employees, and agents
                        from and against any and all liability, damage,
                        loss or expense (including reasonable attorneys'
                        fees and expenses of litigation) incurred by or
                        imposed upon it or any one of them in connection
                        with any claims, suits, actions, demands or
                        judgments arising out of, resulting from or
                        related to performance under this Agreement,
                        regardless of the theory of liability (including,
                        but not

<PAGE>   5

                        limited to, actions in the form of tort, warranty, or
                        strict liability), to the extent that such liability,
                        loss, damage or expense is the result of the acts or
                        omissions of EntreMed or any of its board members,
                        officers, agents, servants, and employees.

            (b)         EntreMed agrees, at its own expense, to provide
                        attorneys reasonably acceptable to the Hospital
                        to defend against any actions brought or filed
                        against any party indemnified hereunder with
                        respect to the subject of indemnity contained
                        herein, whether or not such actions are
                        rightfully brought.  Hospital shall promptly
                        notify EntreMed if any such action shall be
                        brought or filed or claim made.

            (c)         This Article 8 shall survive expiration or termination
                        of this Agreement.

9.          BIOLOGICAL MATERIALS TRANSFER

            (a)         Unique clones, chemicals, proteins or reagents
                        developed or discovered under the Program by
                        Hospital may be shared with scientists at
                        non-profit academic or governmental institutions upon
                        execution of Hospital's Materials Transfer
                        Agreement for commercially significant
                        materials.  Requests for such materials that
                        originate from commercially entities will be
                        discussed with EntreMed, and Hospital will
                        consider the potential effect of such transfers
                        on the Program before deciding whether to
                        transfer such materials.

10.         TIMELY PRE-CLINICAL AND CLINICAL DEVELOPMENT

            (a)         As a condition to obtaining a license to the
                        patent rights to Inventions under Section 7,
                        EntreMed agrees to support clinical development,
                        clinical trial and regulatory management of
                        licensed products.  If EntreMed decides to
                        sublicense the licensed product and patent
                        rights, in whole or for a field of use, the
                        sublicenses must be acceptable to Hospital in
                        that such sublicensee can provide the resources
                        required to bring the Invention to the
                        marketplace.  Such acceptance of a sublicensee by
                        Hospital will not be unreasonably withheld.

            (b)         EntreMed agrees to notify Hospital in a timely
                        way of its decision to discontinue preclinical or
                        clinical development of any licensed product and
                        its reasons for doing so.  The license(s) held by
                        EntreMed to Patent Rights (as defined in the
                        license agreement for such licensed product) for
                        that Licensed Product (as defined in the license
                        agreement for such licensed product) will be
                        terminated upon notice from Hospital.

11.         TERM AND TERMINATION

            (a)         The term of this Agreement begins on the Effective Date
                        and terminates on September 30, 2002, unless sooner
                        terminated as provided below.
<PAGE>   6

            (b)         Performance under this Agreement may be
                        terminated by EntreMed at any time with or
                        without cause, and by Hospital without cause,
                        upon one (1) year prior written notice to the
                        other party.  If Hospital terminates this
                        Agreement under this Article 11(b), all options
                        and rights to Inventions and patent rights
                        granted in this Agreement to EntreMed shall
                        remain in effect under Article 7 and all licenses
                        granted prior to the effective date of
                        termination shall remain in effect subject to the
                        terms of the applicable license agreement entered
                        into between EntreMed and Hospital.  EntreMed
                        shall continue to fund the Program for the
                        shorter of either one year following notice of
                        termination or the remainder of the term set
                        forth in Article 11(a).

            (c)         In the event of termination by EntreMed under
                        Article 11(b), all options and rights to
                        Inventions and patent rights granted in Article 7
                        shall immediately terminate this Agreement and
                        coincidentally with EntreMed's notice of
                        termination.  Any license agreement granted to
                        EntreMed under Article 7 prior to such notice of
                        termination, shall survive, subject to the terms
                        of said license agreement.

            (d)         In the event of EntreMed's material breach of this
                        Agreement, including without limitation, failure to meet
                        its payment obligation under Article 4, Hospital shall
                        have the right to give notice of breach, and EntreMed
                        shall have ninety (90) days to cure such breach.

            (e)         In the event of termination by Hospital under
                        Article 11(b), and upon sending its notice of
                        termination, Hospital agrees to promptly take all
                        responsible steps to reduce the costs to
                        EntreMed, and Hospital shall return at
                        termination any unexpended funds to EntreMed less
                        any non-refundable costs including noncancelable
                        obligations Hospital has incurred in the
                        performance of the Program prior to the date of
                        notice of such termination.  In no event shall
                        such deduction exceed the total support specified
                        in Article 4.

            (f)         In the event of termination under Article 3 and
                        upon the terminating party sending its notice of
                        termination, Hospital agrees to promptly take all
                        responsible steps to reduce the costs to
                        EntreMed, and Hospital shall return at
                        termination any unexpended funds to EntreMed less
                        any non-refundable costs including, but not
                        limited to non-cancelable obligations Hospital
                        has incurred in the performance of the Program
                        prior to the date of notice of such termination.
                        In no event shall such deduction exceed the total
                        support specified in Article 4.  EntreMed agrees
                        to fund salaries of essential personnel for a
                        period of nine months from notice of
                        termination.  All options and rights to
                        Inventions and patent rights granted in Article 7
                        to EntreMed shall remain in effect and all
                        licenses granted prior to the effective date of
                        termination shall remain in effect subject to the
                        terms of the applicable license agreement entered
                        into between EntreMed and Hospital.

<PAGE>   7

            (g)         The following provisions shall survive any expiration or
                        termination of this Agreement: 4(a) as to the Option,
                        5(a), 7(a), 8, 11(b), 11(c), 11(f), 11(g), 12(a), 15
                        (except (b) and (g)) and 16.

12.         COMMUNICATIONS

            (a)         Notice. All medical/scientific and other communications,
                        reports, and notices shall be delivered by hand or sent
                        by first class mail postage prepaid and addressed as
                        follows:

            If to EntreMed:

                        President
                        EntreMed, Inc.
                        9640 Medical Center Drive
                        Rockville, MD  20850

            With a copy to:

                        James Dean Johnson, Ph.D.
                        Jones & Askew
                        2400 Monarch Tower
                        2434 Peachtree Road
                        Atlanta, GA  30326

            If to Hospital:

            For all medical/scientific communications:

                        Robert D'Amato, M.D., Ph.D.
                        Department of Surgery
                        Children's Hospital
                        300 Longwood Avenue
                        Boston, MA  02115-5737

            With a copy to:

                        Director
                        Technology Transfer Office
                        Children's Hospital
                        300 Longwood Avenue
                        Boson, MA  02115-5737

<PAGE>   8

            For all other communications, reports, and notices:

                        Director
                        Technology Transfer Office
                        Children's Hospital
                        300 Longwood Avenue
                        Boston, MA  02115-5737

            (b)         For the purpose of facilitating EntreMed's
                        understanding of the research activities
                        conducted by Hospital pursuant to the Program,
                        Hospital will permit duly authorized employees or
                        representatives of EntreMed to visit its
                        facilities where the research is conducted, or
                        attend restricted-access Hospital seminars on or
                        off site, at reasonable times and with prior
                        reasonable notice and approval by the Principal
                        Investigator.  All such visits, seminars or other
                        communications, including without limitation,
                        informal conversations, email and the like
                        concerning research activities, will be subject
                        to the Mutual Nondisclosure Agreement between the
                        parties of even date as this Agreement.

            (c)         All communications regarding the business terms in this
                        Agreement shall be exclusively between EntreMed and the
                        Technology Transfer Office.

13.         USE OF NAMES

            (a)         Each party agrees not to use or cite in any
                        manner the name of the other, its employees or
                        Principal Investigator in any commercial or
                        non-commercial advertising, article, press release or
                        in any other forms of writing or publication
                        medium, or orally to the extent practical,
                        without the prior written permission of the party
                        or individual whose name is to be used except as
                        required by law.  Hospital agrees to respond to
                        any submission by EntreMed in a timely manner,
                        and EntreMed agrees to submit such writings, and
                        summarized oral comments to the extent practical,
                        for approval at least ten (10) days prior to
                        submission for public release.  EntreMed agrees
                        that any such writings or publications or oral
                        comments or presentations, and any references in
                        its other communications to the public or third
                        parties, will accurately reflect the contractual
                        relationship between the parties and will not
                        misrepresent or mislead others as to the nature
                        of the relationship.  The parties agree to meet
                        within thirty (30) days after the Effective Date
                        to establish a set of rules to assist them in
                        complying with this Article 13(a).

            (b)         EntreMed agrees not to disclose any of Hospital's
                        confidential or proprietary information in
                        Invention disclosures or reports, data concerning
                        scientific discoveries, data from evaluations,
                        research results and the like in any commercial
                        or non-commercial advertising, article, press
                        release or in any other forms of writing or
                        publication medium or to any third party without
                        the prior written permission of Hospital.
<PAGE>   9

14.         REPRESENTATIONS AND WARRANTIES.  HOSPITAL REPRESENTS
            AND WARRANTS TO ENTREMED AS FOLLOWS:

            (a)         The execution and delivery of this Agreement by
                        Hospital have been duly and validly authorized
                        and this Agreement constitutes a legal, valid and
                        binding obligation of Hospital, enforceable in
                        accordance with its terms.  The execution,
                        delivery and performance of this Agreement does
                        not conflict with or violate any charter document
                        or, to Hospital's knowledge, any contract binding
                        upon Hospital.

            (b)         Hospital has not received notice of any assertion that
                        any of the patents or subject Inventions infringe upon
                        any third party's know-how, patent or other intellectual
                        property rights.

            (c)         Hospital is and will be, during the term of this
                        Agreement and thereafter, the owner of all rights in and
                        to the inventions conceived or first reduced to practice
                        by Hospital or its employees or independent contractors
                        as a part of any of the projects which are included in
                        the Program.

            EntreMed represents and warrants to Hospital as follows:

            (a)         The execution and delivery of this Agreement by
                        EntreMed have been duly and validly authorized
                        and this Agreement constitutes a legal, valid and
                        binding obligation of EntreMed enforceable in
                        accordance with its terms.  The execution,
                        delivery and performance of this Agreement does
                        not conflict with or violate any charter document
                        or, to EntreMed's knowledge, any contract binding
                        upon EntreMed.

15.         GENERAL PROVISIONS

            (a)         All rights and remedies hereunder will be cumulative and
                        not alternative, and this Agreement shall be construed
                        and governed by the laws of the Commonwealth of
                        Massachusetts.

            (b)         Neither party may assign, transfer or delegate
                        its rights, duties or obligations hereunder
                        without the prior written consent of the other,
                        and any assignment, transfer or delegation in
                        violation of this provision shall be void.
                        Subject to the terms of this provision, this
                        Agreement shall be binding upon and inure to the
                        benefit of the parties hereto and their
                        respective successors and assigns.
                        Notwithstanding anything herein to the contrary,
                        in the event EntreMed merges with another entity,
                        is acquired by another entity, or sells all or
                        substantially all of its assets to another
                        entity, EntreMed may assign its rights and
                        obligations hereunder to, in the event of a
                        merger or acquisition, the surviving entity, and
                        in the event of a sale, the acquiring entity,
                        without Hospital's consent so long as:  (i)
                        EntreMed is not then in breach of this Agreement;
                        (ii) the proposed assignee has a net worth at
                        least equivalent to the net worth EntreMed had as
                        of the date

<PAGE>   10

                        of this Agreement; (iii) the proposed assignee has
                        available resources and sufficient scientific business
                        and other expertise to satisfy EntreMed's obligations
                        hereunder; (iv) EntreMed provides written notice of the
                        assignment to Hospital, together with documentation
                        sufficient to demonstrate the requirements set forth in
                        subparagraphs (i) through (iii) above, at least twenty
                        (20) days prior to the effective date of the proposed
                        assignment; and (v) Hospital receives from the proposed
                        assignee, in writing, at least twenty (20) days prior to
                        the effective date of the assignment: (aa) reaffirmation
                        of the terms of this Agreement; (bb) an agreement to be
                        bound by the terms of this Agreement; and (cc) an
                        agreement to perform the obligations of EntreMed under
                        this Agreement.

            (c)         This Agreement may be amended only by written agreement
                        signed by both parties.

            (d)         It is expressly agreed by the parties hereto that the
                        Hospital and EntreMed are independent contractors and
                        nothing in this Agreement is intended to create an
                        employer relationship, joint venture, or partnership
                        between the parties. Neither party has the authority to
                        bind the other.

            (e)         This Agreement and its Exhibits constitute the
                        entire agreement between the parties with respect to the
                        subject matter hereof and supersedes all proposals,
                        negotiations and other communications between the
                        parties, whether written or oral, with respect to the
                        subject matter hereof.

            (f)         If any provisions of this Agreement shall be held to be
                        invalid, illegal or unenforceable, the validity,
                        legality and enforceability of the remaining provisions
                        of this Agreement shall not be impaired thereby.

            (g)         The use of vertebrate animals in the conduct of
                        work under this Agreement shall comply with
                        applicable portions of the Animal Welfare Act
                        (P.L. 89-544 as amended) and will follow the
                        guidelines prescribed in DHEW, NIH Publication
                        No. 78-23, "Guide for the Care and Use of
                        Laboratory Animals," as amended, and in any
                        applicable state or local regulations.

            (h)         EXCEPT AS PROVIDED IN ARTICLE 14, AND TO THE
                        EXTENT PERMITTED BY APPLICABLE LAW, HOSPITAL
                        MAKES NO WARRANTY, EXPRESS OR IMPLIED, INCLUDING,
                        WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF
                        MERCHANTABILITY, FITNESS FOR A PARTICULAR
                        PURPOSE, TITLE OR NONINFRINGEMENT, WITH RESPECT
                        TO ANY PATENT, TRADEMARK, COPYRIGHT, SOFTWARE,
                        TRADE SECRET, TANGIBLE RESEARCH PROPERTY,
                        INVENTION, RESEARCH RESULTS, INFORMATION OR DATA
                        PROVIDED OR UNDER OPTION TO ENTREMED HEREUNDER
                        AND HEREBY DISCLAIMS THE SAME, AND HOSPITAL SHALL
                        NOT BE LIABLE

<PAGE>   11

                        FOR ANY DIRECT, CONSEQUENTIAL OR OTHER DAMAGES SUFFERED
                        BY ENTREMED OR ANY LICENSEE OR OTHERS RESULTING FROM USE
                        OF THE SAME OR ANY RESULTING PRODUCT OR PROCESS.

            IN WITNESS WHEREOF, the parties have executed this Agreement as of
the date first written above.

Children's Hospital                            EntreMed, Inc.

By:   /s/ William New                          By: /s/ John W. Holaday, Ph.D.
      -------------------------                    --------------------------

Vice President
Research Administration                        President and CEO
-------------------------------
Title

10/19/99                                       9/22/99
-------------------------------                ------------------------------
Date                                           Date

/s/ Robert D'Amato                             10/22/99
-------------------------------                ------------------------------
Robert D'Amato, M.D., Ph.D.                    Date
Principal Investigator

<PAGE>   12

           Overview of EntreMed funded projects in D'Amato Laboratory

Continuing collaborative projects:

1.          Thalidomide and analogs
                 Testing of analogs and isomers with the phthalimide skeleton

2.          Methoxyestradiol and analogs
                 Testing of analogs with substitutions at 2 position on A ring

3.          Epoxide angiogenesis inhibitors such as arglabin
                 Testing of thalidomide and arglabin analogs with epoxides

New projects:

4.          Purification of potent secreted angiogenesis inhibitors from human
            tumors
                 A.    MG63 osteosarcoma
                 B.    A375 melanoma
                 C.    ST2 gastric carcinoma

5.          Testing of angiogenesis inhibitors on the RPE/VEGF transgenic mouse
                 (Inducible choroidal neovascularization as a model of macular
                  degeneration)
                       Treatment with angiogenesis inhibitors-angiostatin/
                       endostatin

6.          Female reproductive system
                 Endometriosis model-Uterine explants in mice
                       Treatment with angiogenesis

            inhibitors-angiostation/endostatin

7.          Testing of novel inhibitors including new EntreMed compounds and
            gene therapy.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}]]